• Elite Pharmaceuticals Q1 results: revenue fell 20% to $32.36 million, while net income was $5.9 million.
• Gross profit dropped 50% to $13.51 million; gross margin narrowed 26 percentage points to 42%.
• Operating income slid to $7.5 million from $21.7 million a year earlier.
• Research and development expense rose 21% to $2.03 million; total operating expenses increased 8% to $5.98 million.
• Launched generic methadone tablets in April 2026; filed an ANDA for an undisclosed anticoagulant in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037752), on August 13, 2026, and is solely responsible for the information contained therein.